Business context and reporting period
The supplied filing is Pieris Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022. This conflicts with the request metadata identifying Palvella Therapeutics, Inc.; verify the issuer before relying on this summary. Pieris is a clinical-stage biopharmaceutical company developing Anticalin-based respiratory and immuno-oncology therapies. It has no product sales; reported revenue is from collaborations and licenses.
Financial results and position
Amounts below are in U.S. dollars. Income-statement and cash-flow amounts are for the stated periods; balance-sheet amounts are as of the dates shown.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $3.7 million | $3.3 million | $14.7 million | $18.9 million |
| Research and development | $11.9 million | $15.8 million | $26.0 million | $32.4 million |
| General and administrative | $4.1 million | $4.2 million | $8.5 million | $8.4 million |
| Operating loss | $12.3 million | $16.8 million | $19.8 million | $21.8 million |
| Net loss | $10.3 million | $15.5 million | $15.4 million | $19.7 million |
| Loss per share, basic and diluted | $0.14 | $0.25 | $0.21 | $0.33 |
- Liquidity: Cash and cash equivalents were $54.3 million and short-term investments were $26.7 million at June 30, 2022, totaling $80.9 million in cash, cash equivalents and investments, versus $117.8 million in cash and cash equivalents at December 31, 2021.
- Cash flows, six months: Operating activities used $38.2 million, investing activities used $27.8 million, and financing activities provided $6.8 million. The filing attributes investing outflow primarily to purchases of investments. Cash and cash equivalents fell $63.5 million, including a $4.3 million adverse exchange-rate effect.
- Balance sheet: Total assets were $114.3 million, total liabilities $69.9 million, and stockholders’ equity $44.4 million. Liabilities included $44.9 million of deferred revenue and $12.3 million of non-current operating lease liabilities. The filing reports no debt balance.
- Margins: The filing does not present a gross margin. Operating expenses substantially exceeded revenue in both periods.
- Shares: Weighted-average shares for Q2 2022 were 74.1 million, compared with 61.9 million in Q2 2021. The company sold 1.9 million shares through its ATM program in the first half for $6.9 million gross proceeds.
Material changes versus prior comparable periods
- Q2 revenue increased $0.4 million year over year, while first-half revenue declined $4.2 million. The first-half comparison was affected by a $13.0 million AstraZeneca phase 2a milestone recognized in 2021 and changes in collaboration revenue recognition and reimbursable costs.
- First-half R&D expense fell $6.3 million, mainly due to lower respiratory and immuno-oncology program costs; G&A increased slightly by $0.1 million.
- First-half net loss narrowed by $4.2 million. However, operating cash flow moved from $17.8 million provided in the prior-year period to $38.2 million used, with deferred revenue and working-capital movements cited as key drivers.
- Accumulated deficit reached $272.6 million, up from $257.1 million at year-end 2021.
Outlook, commentary, risks and unusual items
- Management expected available funds to support operations for at least 12 months from the August 4, 2022 filing date, while warning that estimates are uncertain and additional capital may be needed. The company expects continued operating losses for at least several years and plans to pursue equity financing, ATM sales, collaborations, licensing, grants and milestones.
- PRS-060/AZD1402’s AstraZeneca-sponsored asthma phase 2a study was ongoing; topline results were expected by Q3 2023. AstraZeneca narrowed the efficacy focus to the 3 mg cohort, stopped enrollment in the 1 mg efficacy cohort, and planned a 10 mg safety cohort only.
- PRS-220 was in clinical-enabling development. The company expected a phase 1 study in healthy volunteers later in 2022 and results in 2023; it reported that the first regulatory filing had been submitted in Australia.
- PRS-344/S095012 was in a phase 1/2 study with Servier; expansion cohorts were expected to begin in 2023. Boston Pharmaceuticals’ PRS-342 phase 1 study was expected to start in the first half of 2023.
- After quarter-end, Pieris announced that enrollment in the cinrebafusp alfa phase 2 study had ceased as part of pipeline prioritization. The filing also describes an August 2022 AstraZeneca amendment extending research on two discovery programs and discontinuing a third.
- A €14.2 million Bavarian grant supports qualifying PRS-220 research and development costs through August 2023, subject to eligibility and grant conditions.
- Key risks include clinical and regulatory uncertainty, reliance on partners for program advancement and milestone or royalty payments, need for additional financing, potential dilution, manufacturing and third-party dependencies, and foreign-exchange exposure. Management stated there were no material changes to the risk factors in its 2021 Form 10-K and no material pending legal proceedings.
- Deferred revenue declined by $14.3 million in the first half; collaboration revenue is subject to estimates and performance obligations. The filing reports no material off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer: the supplied filing names Pieris Pharmaceuticals, Inc., not Palvella Therapeutics, Inc.
- Check whether the stated 12-month cash runway remains adequate given the $38.2 million first-half operating cash outflow and expected ongoing losses.
- Track clinical updates and partner decisions for PRS-060/AZD1402, PRS-220, PRS-344/S095012, and the programs affected by the cinrebafusp alfa and AstraZeneca portfolio changes.
- Assess reliance on future financings and collaboration-based revenue, including the potential dilution from ATM sales and the uncertainty of milestone payments.
- Review the August 2022 post-quarter developments and confirm their effects on program plans and expected cash needs.